GYRE vs SGMT
GYRE: A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market. SGMT: Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other metabolic diseases.
Side-by-side fundamentals
| Metric | GYRE | SGMT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.94 | $7.05 | |
| Market cap as of 2026-07-23 | $667M | $431M | |
| P/E as of 2026-07-23 | 132.62 | n/a | |
| Net margin as of 2026-07-23 | -5.4% | -1393.8% | GYRE higher |
| Gross margin as of 2026-07-23 | +95.1% | n/a | |
| Operating margin as of 2026-07-23 | -0.1% | -1537.0% | GYRE higher |
| ROE as of 2026-07-23 | -6.3% | -37.6% | GYRE higher |
| ROA as of 2026-07-23 | -4.0% | -35.5% | GYRE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +16.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +4.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 2.36 | 3.45 | |
| 1-year return as of 2026-07-22 close | -17.8% | -26.6% | GYRE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.